Specifically, combination therapy of ursodeoxycholic acid (UDCA) with the INT-747 in phase II clinical trials in PBC patients not responding to UDCA showed substantial reduction of biochemical parameters of liver damage and cholestasis, such as ALT and ALP, after short-term and long-term administration.95,96 In line with the results obtained with combination therapy, INT-747 monotherapy in PBC patients also achieved a significant reduction of serum markers of liver damage and cholestasis after 12 weeks of treatment.97 Here, GPT is linked to cholestasis.